S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
NYSE:PBH

Prestige Consumer Healthcare (PBH) Stock Forecast, Price & News

$58.50
+1.80 (+3.17%)
(As of 06/2/2023 ET)
Compare
Today's Range
$56.79
$58.51
50-Day Range
$56.70
$63.76
52-Week Range
$48.51
$67.45
Volume
295,432 shs
Average Volume
222,395 shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.25

Prestige Consumer Healthcare MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
35.5% Upside
$79.25 Price Target
Short Interest
Bearish
2.44% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
0.90mentions of Prestige Consumer Healthcare in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
6.98%
From $4.30 to $4.60 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Consumer Discretionary Sector

134th out of 269 stocks

Pharmaceutical Preparations Industry

154th out of 486 stocks


PBH stock logo

About Prestige Consumer Healthcare (NYSE:PBH) Stock

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Receive PBH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prestige Consumer Healthcare and its competitors with MarketBeat's FREE daily newsletter.

PBH Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Continuing To Avoid Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc. (PBH)
See More Headlines

PBH Price History

PBH Company Calendar

Last Earnings
5/04/2023
Today
6/03/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
CUSIP
74112D10
Employees
505
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$79.25
High Stock Price Forecast
$104.00
Low Stock Price Forecast
$71.00
Forecasted Upside/Downside
+35.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-82,310,000.00
Pretax Margin
-8.33%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.17 per share
Book Value
$29.12 per share

Miscellaneous

Free Float
48,898,000
Market Cap
$2.91 billion
Optionable
Optionable
Beta
0.56

Key Executives

  • Ronald M. LombardiRonald M. Lombardi
    Chairman, President & Chief Executive Officer
  • Jeff Zerillo
    Senior Vice President-Operations
  • Christine Sacco
    Chief Financial Officer
  • William C. P'Pool
    Secretary, Senior Vice President & General Counsel
  • Adel Mekhail
    Executive Vice President-Marketing & Sales













PBH Stock - Frequently Asked Questions

Should I buy or sell Prestige Consumer Healthcare stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PBH shares.
View PBH analyst ratings
or view top-rated stocks.

What is Prestige Consumer Healthcare's stock price forecast for 2023?

5 Wall Street analysts have issued 12 month target prices for Prestige Consumer Healthcare's stock. Their PBH share price forecasts range from $71.00 to $104.00. On average, they predict the company's stock price to reach $79.25 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for PBH
or view top-rated stocks among Wall Street analysts.

How have PBH shares performed in 2023?

Prestige Consumer Healthcare's stock was trading at $62.60 at the beginning of 2023. Since then, PBH shares have decreased by 6.5% and is now trading at $58.50.
View the best growth stocks for 2023 here
.

When is Prestige Consumer Healthcare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PBH earnings forecast
.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its earnings results on Thursday, May, 4th. The company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.03. The business earned $285.90 million during the quarter, compared to the consensus estimate of $280.58 million. Prestige Consumer Healthcare had a positive trailing twelve-month return on equity of 13.38% and a negative net margin of 7.30%. The firm's revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 earnings per share.

Is Prestige Consumer Healthcare a good dividend stock?

Prestige Consumer Healthcare (NYSE:PBH) pays an annual dividend of $1.90 per share and currently has a dividend yield of 0.00%.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $4.27-$4.32 for the period, compared to the consensus earnings per share estimate of $4.18. The company issued revenue guidance of $1.14 billion-$1.14 billion, compared to the consensus revenue estimate of $1.12 billion.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.35%), Dimensional Fund Advisors LP (7.40%), Macquarie Group Ltd. (5.54%), State Street Corp (3.85%), FMR LLC (2.14%) and Geode Capital Management LLC (2.07%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends
.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $58.50.

How much money does Prestige Consumer Healthcare make?

Prestige Consumer Healthcare (NYSE:PBH) has a market capitalization of $2.91 billion and generates $1.13 billion in revenue each year. The company earns $-82,310,000.00 in net income (profit) each year or ($1.68) on an earnings per share basis.

How many employees does Prestige Consumer Healthcare have?

The company employs 505 workers across the globe.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The official website for the company is www.prestigebrands.com. The company can be reached via phone at (914) 524-6800, via email at irinquiries@prestigebrands.com, or via fax at 302-674-5266.

This page (NYSE:PBH) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -